This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: January 29, 2008
Last updated: April 6, 2011
Last verified: April 2011
This is a study to investigate the effectiveness and safety of [S,S]-Reboxetine in relieving the symptoms of Fibromyalgia in patients. A previous study demonstrated clinically meaningful treatment effects in fibromyalgia, based on pain and functional endpoints.

Condition Intervention Phase
Fibromyalgia Drug: [S,S]-Reboxetine Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 14-week, Randomized, Double-blind, Placebo-controlled, Multi-center Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily (O.D.) in Patients With Fibromyalgia

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Change from baseline in the endpoint mean pain score [ Time Frame: 14 weeks ]
  • Fibromyalgia Impact Questionnaire [ Time Frame: 14 weeks ]

Secondary Outcome Measures:
  • Change from baseline in the endpoint mean sleep interference score [ Time Frame: 14 weeks ]
  • Patient Global Impression of Change [ Time Frame: 14 weeks ]
  • Multidimensional Assessment of Fatigue [ Time Frame: 14 weeks ]
  • Hospital Anxiety and Depression Scale [ Time Frame: 14 weeks ]
  • Short Form 36 [ Time Frame: 14 weeks ]
  • Sheehan Disability Score [ Time Frame: 14 weeks ]
  • Pain Visual Analogue Scale [ Time Frame: 14 weeks ]

Enrollment: 1129
Study Start Date: December 2007
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 3 Drug: [S,S]-Reboxetine
10 mg oral tablet once a day dosing
Sham Comparator: 4 Drug: Placebo
0 mg oral tablet once a day dosing
Experimental: 1 Drug: [S,S]-Reboxetine
4 mg oral tablet once a day dosing
Experimental: 2 Drug: [S,S]-Reboxetine
8 mg oral tablet once a day dosing


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female of any race, at least 18 years of age
  • Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites)

Exclusion Criteria:

  • Patients with other severe pain (eg, Diabetic Peripheral Neuropathy and PostHerpetic Neuralgia) that may confound assessment or self evaluation of the pain associated with fibromyalgia
  • Patients with any autoimmune rheumatic disorder, non-focal rheumatic disease (other than fibromyalgia), active infection, or untreated endocrine disorder
  • A current or recent diagnosis (last 6 months) or episode of major depressive disorder, dysthymia and/or uncontrolled depression
  • History of mania, hypomania, other psychotic disorder, or current mood disorder with psychotic features
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00612170

  Show 146 Study Locations
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer Inc Identifier: NCT00612170     History of Changes
Other Study ID Numbers: A6061043
Study First Received: January 29, 2008
Last Updated: April 6, 2011

Keywords provided by Pfizer:
Phase 3, safety and efficacy study, [S,S[-Reboxetine, Fibromyalgia

Additional relevant MeSH terms:
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases
Antidepressive Agents
Psychotropic Drugs
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs processed this record on September 21, 2017